In hepatocellular carcinoma, glutaminase 1 enhances stemness by reducing ROS.[26] Conversely, in breast cancer, lowering ROS levels diminishes cancer cell stemness by downregulating HIF2α.[27] These results suggest that ROS can either promote or inhibit cancer cell stemness by disrupting intracellular ROS homeostasis or triggering different cascade signaling responses. Here, EPAS1 is linked to hepatocellular carcinoma.